O-2220

O-2220
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

O-2220 is a chemical compound that has been studied for its potential effects on the endocannabinoid system. It is classified as a cannabinoid receptor agonist, specifically targeting the CB1 receptor.

Chemical Structure and Properties

O-2220 is a synthetic compound with a complex chemical structure. The molecular formula and specific stereochemistry are crucial for its activity at the cannabinoid receptors. The compound is typically synthesized in a laboratory setting and is not found naturally.

Pharmacology

O-2220 acts as a selective agonist for the CB1 receptor, which is predominantly found in the central nervous system. Activation of the CB1 receptor by O-2220 can lead to various physiological effects, including modulation of neurotransmitter release, alteration of pain perception, and changes in appetite.

Mechanism of Action

The mechanism by which O-2220 exerts its effects involves binding to the CB1 receptor, a G-protein coupled receptor, leading to the inhibition of adenylate cyclase activity. This results in decreased levels of cyclic AMP and subsequent downstream effects that modulate neuronal excitability and neurotransmitter release.

Potential Applications

Research into O-2220 has primarily focused on its potential therapeutic applications. These include:

• Pain Management: Due to its action on the CB1 receptor, O-2220 may have analgesic properties that could be beneficial in managing chronic pain conditions.
• Appetite Stimulation: Similar to other CB1 agonists, O-2220 might be used to stimulate appetite in conditions such as cachexia or anorexia.

Research and Development

O-2220 is still under investigation, and much of the research is preclinical. Studies are ongoing to better understand its pharmacokinetics, safety profile, and potential therapeutic uses.

Safety and Toxicology

As with many synthetic cannabinoids, the safety profile of O-2220 is not fully established. Potential side effects could include those commonly associated with CB1 receptor activation, such as dizziness, dry mouth, and altered mental status.

Legal Status

The legal status of O-2220 varies by jurisdiction. It is important for researchers and clinicians to be aware of the regulatory framework governing the use of synthetic cannabinoids in their region.

Also see

• Cannabinoid receptor
• CB1 receptor
• Endocannabinoid system
• Synthetic cannabinoids